JNK2 Antibody (YA5409)

JNK2 (MAPK9) is a member of the c-Jun N-terminal kinase (JNK) family, a stress-activated branch of the mitogen-activated protein kinase (MAPK) network that transduces extracellular stress, cytokine, and growth-factor signals into cellular responses regulating proliferation, survival, apoptosis, differentiation, and inflammation^[1][2]. Mechanistically, JNK signaling is activated through a kinase cascade involving MAP3Ks, MKK4, and MKK7, leading to phosphorylation of transcriptional regulators such as c-Jun and other stress-responsive substrates that control gene expression programs^[3][4]. In disease-associated contexts, dysregulated JNK signaling has been linked to cancer, obesity, type 2 diabetes, inflammatory disorders, neurodegenerative diseases, and pathological cell death, making the pathway a widely studied experimental target^[1][2][3]. Compared with related isoforms, JNK1 and JNK2 are broadly expressed across tissues, whereas JNK3 shows a more restricted distribution, primarily in the brain, heart, and testis^[1][3]. Importantly, JNK1 and JNK2 can exhibit both redundant and opposing biological functions, and experimental studies have demonstrated that JNK1, but not JNK2, is required for specific TNF-α-induced responses including c-Jun kinase activation and apoptosis, highlighting isoform-specific signaling properties^[1][4]. For experimental applications, the growing recognition of isoform-dependent JNK biology has stimulated the development of JNK inhibitors, with current research emphasizing improved selectivity and on-target specificity for mechanistic studies and therapeutic evaluation^[1][2].